Validation of RRx-001 as a novel disease-modifying therapeutic for Parkinson’s disease
Principal Investigator(s): Dr Tony Reid, Dr Bryan Oronsky and Dr Richard Gordon
Project Title: Validation of RRx-001 as a novel disease-modifying therapeutic for Parkinson’s disease
Our project will test the effectiveness of a new treatment for Parkinson’s disease (PD), called RRx-001. We believe this drug could be beneficial in PD by blocking inflammasome activation and other mechanisms which drives persistent inflammation that is linked to PD progression.
We propose that RRx-001 could be a safe and effective treatment for Parkinson’s based on our results in animal models and our ongoing human clinical trials with this drug in other conditions.
This project will test the effectiveness of RRx-001 in multiple animal models of Parkinson’s disease and also in cell culture studies. We will determine if RRx-001 can prevent or rescue key aspects of Parkinson’s pathology in disease models, which would indicate that this drug could have potential to work in human studies.
Impact on Diagnosis/Treatment of Parkinson’s disease:
There are currently no treatments for PD. Our drug has been shown to be safe and well-tolerated in human clinical trials date with no major adverse events reported. Therefore, if our testing of RRx-001 in PD models is successful in this project, it can directly enter clinical trials for PD as a new treatment.
Next Steps for Development:
If results of our testing in animal models are positive, we will seek additional funding to progress this drug into human clinical trials.